BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 96   

Articles published

BCRX 11.70 +0.28 (2.45%)
price chart
Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's Strong On High ...
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
Morning Top Movers: Zoetis Inc. (ZTS), BioCryst Pharmaceuticals, Inc. (BCRX ...  WallStreet Scope
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Analyst Rating Update
Wall Street analysts polled by Zacks Research have given BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a rating of 1.29 on a consensus basis.
Large Outflow of Money Witnessed in BioCryst Pharmaceuticals, Inc.
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) advanced to $11.99. The price had gained 4.53% or 0.52 points intraday.
Zacks Short Term Rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)  American Trade Journal
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Rally 2.65%  Insider Trading Report
BioCryst Pharmaceuticals, Inc. Short Interest Update
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ensharesed a drop of 4.9% or -408,587 shares in the short positions. The number dropped from 8,384,510 on July 31,2015 to 7,975,923 on August 14,2015.
Biotech Stocks to bet on: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ...  Wall Street Point
BioCryst Pharmaceuticals Receives Average Rating of "Buy" from ...  Dakota Financial News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target Update
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): 6 analysts have set the short term price target of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) at $19.17. The standard deviation of short term price target has been estimated at $2.86, implying that the ...
Company Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Drops by -4.75%
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has lost 4.75% during the past week and dropped 26.23% in the last 4 weeks.
Durham's BioCryst cuts $45 million deal with Australian firm
Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq: BCRX) licensed its recently approved flu treatment Rapivap in a deal that could bring the company $45 million plus sales royalties.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has licensed RAPIVAB (peramivir ...  Inside Trade
BioCryst Pharma licenses flu med to CSL Limited (BCRX)  Seeking Alpha
Earnings Preview: Groupon Inc, BioCryst Pharmaceuticals, Inc., and Cablevision ...
Tomorrow could be more of the same, with coupon concern Groupon Inc (NASDAQ:GRPN), drugmaker BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and cable operator Cablevision Systems Corporation (NYSE:CVC) all on deck. Below, we'll take the ...
Company Update (NASDAQ:BCRX): BioCryst Pharmaceuticals, Inc. Reports 2Q:15 ...  Smarter Analyst
Analyst Rating Update on BioCryst Pharmaceuticals, Inc.  OTC Outlook
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Business Summary
[Zacks] BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)(TREND ANALYSIS) One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is BioCryst Pharmaceuticals, Inc. (BCRX). This Medical-Drugs stock has ...
BioCryst Pharmaceuticals, Inc. Price Target Update  Money Flow Index
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Large Outflow of ...  American Trade Journal
Why BioCryst Pharmaceuticals, Inc. Shares Scorched Higher
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a predominantly clinical-stage biotech company focused on developing novel small molecule drugs to treat varying diseases, scorched higher by as much as 12% in Wednesday's trading session ...
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Adds 5.4%  Zacks.com
Ebola Finances Coming Back in the News  24/7 Wall St.